<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337479</url>
  </required_header>
  <id_info>
    <org_study_id>AI463-049</org_study_id>
    <nct_id>NCT01337479</nct_id>
  </id_info>
  <brief_title>A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials</brief_title>
  <official_title>Long-Term Assessment of Treatment Outcomes With Entecavir and Lamivudine for Chronic Hepatitis B Infection in Patients Who Have Enrolled in Phase III Entecavir Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to follow patients treated in entecavir Phase III and rollover
      studies for safety experience and Hepatitis B virus (HBV)-related complications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational Model: Only subjects who participated in Entecavir Phase III studies AI463022,
      AI463023, AI463026, and AI463027.

      Number of groups/cohorts: 1 (All subjects were observed in the same manner).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of subjects who have newly reported hepatitis B-related complications during AI463049 (reported by Phase III treatment groups)</measure>
    <time_frame>data is collected every 6 months</time_frame>
    <description>defined as follows:
Hepatic cirrhosis (Diagnosis requires biopsy or imaging study)
Esophageal Varices (Grade 1 or higher on endoscopy or barium swallow)
Bleeding esophageal varices
Ascites (Present on physical exam or imaging study)
Hepatic encephalopathy (≥ Stage 2)
Hepatocellular carcinoma
Spontaneous bacterial peritonitis
Gastric varices
Bleeding gastric varices
Hepatorenal syndrome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of subjects who have a HBV Deoxyribonucleic acid (DNA) by Polymerase chain reaction (PCR) of &lt; 300 copies/mL over the AI463049 follow-up period by the phase III treatment group</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of subjects who have Alanine transaminase (ALT) ≤ 1.0 x Upper limit of normal (ULN) over the AI463049 follow-up period by the phase III treatment group</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of subjects who were Hepatitis B e antigen (HBeAg) positive at the beginning of Phase III trials who have HBeAg loss or HBe seroconversion over the AI463049 follow-up period by the phase III treatment group</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the number of anti-HBV medications following enrollment in AI463049 by the phase III treatment group</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine all cause mortality by the phase III treatment group</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine HBV-related mortality by the phase III treatment group</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine Non-hepatic malignancies by the phase III treatment group</measure>
    <time_frame>Every 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1097</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Participants of specific phase III entecavir studies</arm_group_label>
    <description>Those who participated in the specific Phase III entecavir studies as described; all had Hepatitis B infections</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Only subjects who participated in Entecavir Phase III studies AI463022, AI463023, AI463026,
        and AI463027.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects who participated in Entecavir Phase III studies AI463022, AI463023,
             AI463026, and AI463027.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/home.aspx</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>April 18, 2011</last_update_submitted>
  <last_update_submitted_qc>April 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

